Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Pharmaust Limited ( (AU:NUZ) ) is now available.
Neurizon Therapeutics has raised approximately $5.88 million through a well-supported pro-rata non-renounceable entitlement offer, issuing around 73.5 million new shares at $0.08 each, including strong oversubscription demand from eligible shareholders. The proceeds bolster the company’s balance sheet and provide additional flexibility to fund regulatory, manufacturing and operational activities tied to advancing its lead candidate NUZ-001 in the HEALEY ALS Platform Trial, where Neurizon remains fully funded to complete participation and is targeting first patient dosing in the first quarter of calendar 2026; the company also retains discretion to place a substantial shortfall of shares within three months, which could further support its clinical development strategy and broaden its shareholder base.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative diseases. Its lead drug candidate, NUZ-001, is being developed for amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease, with a strategy to accelerate patient access to effective ALS therapies while exploring broader neurodegenerative indications through international collaborations and rigorous clinical programs.
Average Trading Volume: 502,645
Technical Sentiment Signal: Sell
Current Market Cap: A$80.46M
Learn more about NUZ stock on TipRanks’ Stock Analysis page.